No Clear Error to Find Lack of Written Description for a Method of Treatment Patent Despite Separate Disclosures of the Drug, Disease, and Dose (as Part of a Range) | Haug Partners LLP

Biogen International GMBH, Biogen MA, Inc., v. Mylan Pharmaceuticals Inc. marks the Federal Circuit’s most recent interpretation of the 35 U.S.C. § 112 written description requirement...

Related Keywords

West Virginia ,United States , ,Biogen Ma Inc ,District Court Finds Lack Of Written Description ,Biogen International ,Mylan Pharmaceuticals Inc ,Federal Circuit ,District Court Finds Lack ,Northern District ,Broad Specification ,Drug Discovery ,Not Clinical Efficacy ,Related Methods ,Doses Included Ineffective ,Not Linked ,Clinical Data ,Multiple Sclerosis ,Clinical Efficacy ,Therapeutic Efficacy ,Judgeo Malley ,